Bill Ackman

Bill Ackman

Last Update: 2015-02-17

Number of Stocks: 7
Number of New Stocks: 1

Total Value: $16,043 Mil
Q/Q Turnover: 20%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Bill Ackman Watch

  • Bill Ackman is keeping on buying Zoetis

    Bill Ackman, co-investment manager for hedge-fund group Gotham Partners LP, formed Pershing Square in November 2003 with $54 million raised from three investors. Ackman got his start in the real estate business, where he worked for his father prior to starting Gotham.

    He is an activist investor. He buys the common stocks of public companies, and pushes for changes so that the market can realize the values of the companies. Ackman buys stocks trading at a discount, and sells when the companies reach their appraised value.


  • Bill Ackman Describes The Impact Activists Have On Businesses

    Are activist investors the friend of the long term shareholder or simply predators looking to make a fast buck?

    There likely isn't a simple answer to that question.


  • Activist Investor Bill Ackman's Newest Additions to His Portfolio

    Bill Ackman (Trades, Portfolio) of Pershing Square Capital Management, L.P. is known for being an activist investor as well as a philanthropist. Ackman, along with guru Bruce Berkowitz (Trades, Portfolio) and Joseph Steinberg, donated funds to the Center for Jewish History. It was the largest gift the center has ever received. Ackman alone donated almost $7 million because his family says, "we want our children to know, not only their living relatives, but those representing past generations for a greater connection to their family and ancestral origin and heritage."

    Ackman is also active in The Giving Pledge, started by guru Warren Buffett (Trades, Portfolio) along with Bill Gates (Trades, Portfolio) and his wife, in which he committed 50% of his wealth to go to charitable causes.


  • How Good is Your Argument?

    “One of the best ways to get confidence in an idea is to find the best argument out there and see if there is a case that you haven’t considered or if there is something you don’t know. If what I’ve heard are the best arguments that can be made against being short Herbalife, then I want to be short more.”


  • Herbalife's Faceoff Against Financial Market Coup

    Globally known MLM based healthcare product maker Herbalife (HLF) has some major players in finance betting against the company due to its controversial practices. Ever since the US dollar had been gaining in strength since November 2014 versus other major currencies, and also the news of pending probes against the company coming to light, the stock seems to be going downhill. After Herbalife had posted its below-expected earning of Q3 2014, analysts like Timothy Ramey of Pivotal Research Group, has come down heavily to cut down on estimates of the stock price, from $110 to $75. The EPS estimates have been cropped as well, going from $1.34 to $1.22, alongside the 2015 full-year estimates, going down from $5.50 to $5.00. The net income from Q3 2014 went down by as much as 92%, owing to the pre-tax charges it faces from the reassessment of audit of assets and liabilities in the Venezuelan Bolivar. In short, there are problems all around.


  • Bill Ackman: Interview Transcripts Part 1

    STEPHANIE RUHLE, HOST: Bill Ackman (Trades, Portfolio), would you have guessed it, he is just a laugh riot over here? Bill, you just left the stage. You were sitting down with Ray Dalio (Trades, Portfolio). And for me watching two iconic investors sort of go through their investment practice was extraordinary. What did you learn from Ray?

    BILL ACKMAN, FOUNDER, CEO, PERSHING SQUARE CAPITAL: I learned a lot. I mean I really didn’t know how he did what he does. I’m sure I completely understand at this point. But remarkable how he’s built his company and his organization and his approach. And I (INAUDIBLE)…


  • Bill Ackman: JCPenney Is Probably The Worst Investment I've Made…

    In an interview to appear on FOX Business Network’s Risk & Reward at 1PM/ET today, anchor Deirdre Bolton speaks with Pershing Square Capital Management Fonder and CEO Bill Ackman (Trades, Portfolio) following the Harbor Investment Conference. When asked what his biggest strategic mistake was, Ackamn said, “I think JCPenney (JCP) is probably the worst investment I've made.” Ackman also commented on Howard Hughes Corp saying, “I don't think I will ever sell. And that's a pretty long time frame.” When asked if he wasn’t an investor what profession he would be interested in Ackamn says, “an investigative reporter.”

    On his biggest strategic mistake:


  • Graham And Doddsville – Winter 2015 Issue

  • Herbalife after option expiry - Part II: counting shorts and longs

    With Herbalife at $31 then any puts that Ackman has (and we know the prices of them) are in the money so far that their delta is almost one.


  • Herbalife after the January option expiry: Part 1

    I have deliberately refrained from writing about Herbalife until the 17 January 2015 option expiry.

    We know from public disclosures that Pershing Square (PSQ) had a huge put option position on Herbalife.

    There were also a vast number of put options that expired on 17 January.

    Here are the outstanding in-the-money put contracts as at market close Friday.


  • Bill Ackman Says Benefits Of Oil Price Drop Outweigh Costs

    Bill Ackman (Trades, Portfolio)'s assets under management have grown from $11 billion to $18 billion over the past year.

    As far as investing opportunities that he is looking for, Ackman says it is the same as always. He wants to invest in large, high quality companies that have been mismanaged or are undervalued for fixable reasons.


  • The Latest Bill Ackman Video On The Herbalife Pyramid Scheme

    The Bill Ackman (Trades, Portfolio) pursuit of Herbalife continues.

    In his latest video Ackman goes through the mechanics of what a pyramid scheme truly is.  

  • Analysts Make Bullish Ratings in Response to Valeant’s Increased 2015 Guidance

    Valeant Pharmaceuticals (NYSE: VRX) held a conference call with investors on Thursday, January 8, in which the company increased its guidance for 2015. Initially, Valeant had predicted $9.1 billion in revenue and $10 cash earnings per share for 2015. They increased estimates to $9.2 to $9.3 billion in revenue and $10.10 to $10.40 cash earnings per share. Shares spiked nearly 6.9% during intraday trading after the announcement, jumping from $145 to $155.

    Valeant is a diverse pharmaceutical company that offers both over-the-counter and prescription drugs. Most of their drugs focus on dermatological needs and eye health, though their drugs cover a wide array of needs.


  • Love Him Or Hate Him, Bill Ackman Now Runs The World's Top Hedge Fund

    Lunch was a bit awkward. It was around 1 p.m. on a warm October day in New York. A group of Wall Street investors were tucking into chicken in a red-wine demi-glace and Brussels sprouts at the Plaza Hotel. They’d convened for Jim Grant’s fall conference, hosted by the influential editor of Grant’s Interest Rate Observer.

    The lunch speaker was Marty Lipton, legendary lawyer and veteran defender of management in countless proxy battles, hostile takeovers and corporate raids. His talk, which he had titled “Activist Interventions and the Destruction of Long-Term Value,” took aim at a strategy being used with increasing success against his clients and other corporations.


  • Year End Review: Fast-Food Services

    2014 was an eventful year for the fast-food service industry. Which restaurant chains came out ahead, and which ones trailed behind?



  • The Man Who Taught Warren Buffett How To Manage A Company

    Disciples of the investing firm Berkshire Hathaway and its legendary leader, Warren Buffett (Trades, Portfolio), know that his mentors in investing were Benjamin Graham and Charlie Munger (Trades, Portfolio). But when Lawrence Cunningham, author of the recently-published Berkshire Beyond Buffett, asked the Berkshire CEO who should write the foreword, Buffett immediately suggested his friend of more than 40 years – Tom Murphy.

    “Most of what I learned about management, I learned from Murph,” Buffett told Cunningham. “I kick myself because I should have applied it much earlier.”


  • Zoetis in a Growing Global Animal Health Industry

    In this article, let's take a look at Zoetis Inc (ZTS), a $22.24 billion market cap company that is a global leader in the animal health products industry emerged as a separate entity following its spin-off from Pfizer (PFE) in June 2013.

    Favorable industry


  • The "Circle of Competence Trap" – Retail, Energy and Metal Sectors

    “I’m no genius. I’m smart in spots – but I stay around those spots.”

    Tom Watson Sr., Founder of IBM


  • Ackman’s Pershing Square Buys Stake in Zoetis

    Zoetis, Inc. (NYSE: ZTS) is an animal health company that produces vaccines for pets and livestock. Based in Florham Park, New Jersey, the animal health company was once a subsidiary of Pfizer (PFE) but became independent in February 2013. Bill Ackman (Trades, Portfolio), the philanthropic founder and CEO of Pershing Square Capital Management, bought an 8.5% stake in Zoetis for roughly $2 billion on November 11. Additionally, Zoetis released its third quarter report on November 4, topping analysts' expectations.

    Highlights from the Q3 report include a reported $0.41 earnings per share on an adjusted diluted basis, a 21% year-over-year increase. This figure beat the analyst consensus of $0.37 by $0.04. Revenue for the third quarter met the analyst estimate of $1.2 billion; a 10% year-over-year increase. CEO Juan Ramón Alaix attributed the performance to “13% operational revenue growth in our livestock products and continued discipline around our operating expenses.”


  • Bob Olstein On 'Boring' Stocks Printing Money

    Bob Olstein, chairman and CIO of Olstein Funds, is known  as one of the leading experts in corporate disclosure and reporting practices. He wrote an incredible book, The Quality of Earnings, which helped push the use of forensic accounting techniques to identify certain factors in determining a company's future earnings power. (I highly recommend this book.)

    Olstein gives his take on "boring" stocks and how much money they can make in free cash flow. This will translate into investment returns over time.


  • Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    ReplyGm1 - 5 months ago
    Dear Sirs / Madams,

    I am so interested in Pershing Square, would you please advise me its performance and cost? Thank you.

    ReplySamchell@yahoo - 10 months ago
    Some stocks are best evaluated by hands-on personal empiricism. After going into a Walgreen's store, it's manifestly clear where it ranks compared to CVS or Rite Aid. As for Ackman's attraction to Mondelez, perhaps he likes some of the company's snack items, and no doubt enough other consumers will share his taste to move the stock in a positive direction. But anyone looking for more something more dramatic would be better advised to take note of the population's compulsive consumption of Hershey products. (Twizzler's Twist 'n Pull Cherry Licorice is candy heroin.) Also, like Coke and Kleenex, Hershey's is a brand name that's synonymous with the product. (When's the last time your spouse asked you to go to Walgreen's to pick up a "Mondelez Bar"?) In short, investing is a game of guessing, supported by past predilections and indicators that "may" have a bearing on future results. But 50% of stock picking is playing hunches. Never ignore the intangibles as well as personal impressions--that's can't be charted or measured by most systems.

    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial